ENTRADA THERAPEUTICS, INC. Increase (Decrease) in Income Taxes Payable
ENTRADA THERAPEUTICS, INC. (TRDA) reported Increase (Decrease) in Income Taxes Payable of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. increase (decrease) in income taxes payable for the quarter ending 2026-06-30 was $0.00.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in income taxes payable for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in income taxes payable for the quarter ending 2025-12-31 was -$620.00K.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in income taxes payable for the quarter ending 2025-09-30 was $620.00K.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in income taxes payable for fiscal 2025 was -$667.00K.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in income taxes payable for fiscal 2024 was -$3.36M, a 183.42% decline from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in income taxes payable for fiscal 2023 was $4.02M.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in income taxes payable for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Income Taxes Payable 3 month | Increase (Decrease) in Income Taxes Payable 6 month | Increase (Decrease) in Income Taxes Payable 9 month | Increase (Decrease) in Income Taxes Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | -$620.00K derived: sum of 3 quarters · filed 2026-08-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | -$620.00K derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | -$802.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$620.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | -$802.00K derived: sum of 3 quarters · filed 2026-08-05 | -$667.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $620.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$182.00K derived: sum of 2 quarters · filed 2026-08-05 | -$47.00K 10-Q · filed 2025-11-06 | -$1.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$802.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$667.00K 10-Q · filed 2026-08-05 | -$2.25M derived: sum of 3 quarters · filed 2026-08-05 | -$4.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $135.00K 10-Q · filed 2026-05-07 | -$1.45M derived: sum of 2 quarters · filed 2026-05-07 | -$3.31M derived: sum of 3 quarters · filed 2026-05-07 | -$5.05M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.44M derived: sum of 2 quarters · filed 2026-02-26 | -$5.19M derived: sum of 3 quarters · filed 2026-02-26 | -$3.36M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.60M derived: sum of 2 quarters · filed 2025-11-06 | -$1.77M 10-Q · filed 2025-11-06 | $2.25M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$1.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $87.00K 10-Q · filed 2025-08-06 | $4.11M derived: sum of 3 quarters · filed 2025-08-06 | -$3.25M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $1.83M 10-Q · filed 2025-05-08 | $5.86M derived: sum of 2 quarters · filed 2025-05-08 | -$1.50M derived: sum of 3 quarters · filed 2025-05-08 | $5.86M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $4.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$3.33M derived: sum of 2 quarters · filed 2025-02-27 | $4.02M derived: sum of 3 quarters · filed 2025-02-27 | $4.02M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$7.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $0.00 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $7.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $7.36M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-13 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |